Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower - 2Schools to start reopening after Nigeria mass abduction
- 3Car Investigation: A Survey of \Past the Outside\ Car
- 4China's 'Venice Of The East' Is A Historic Canal City Near Shanghai With Arched Bridges And Lantern-Lit Waterways
- 5Spain breaks jobs record with 22 million Social Security contributors
- The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown?
- 'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- 15 Preposterous Cosplay Ensembles That Will Blow You Away
- Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
- ‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
- Miss 'Stranger Things' already? Here's how you can get your Upside Down fix in 2026 with spinoffs, games and more
